Quantbot Technologies LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 132 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2016. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
Quantbot Technologies LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$552,258
+0.8%
10,602
+22.5%
0.04%
+2.8%
Q2 2023$548,098
-5.4%
8,656
-19.1%
0.04%
-12.2%
Q1 2023$579,080
+952.9%
10,694
+799.4%
0.04%
+925.0%
Q3 2022$55,000
-90.9%
1,189
-89.7%
0.00%
-91.8%
Q4 2021$604,000
+1625.7%
11,554
+730.6%
0.05%
+1125.0%
Q3 2020$35,000
-64.3%
1,391
-89.4%
0.00%
-60.0%
Q3 2019$98,000
+1300.0%
13,174
+1845.9%
0.01%
+900.0%
Q4 2018$7,000
-93.0%
677
-85.3%
0.00%
-85.7%
Q3 2018$100,000
+9900.0%
4,609
+5520.7%
0.01%
Q2 2018$1,000
-99.2%
82
-98.6%
0.00%
-100.0%
Q1 2018$119,000
+133.3%
5,698
+61.2%
0.01%
+100.0%
Q4 2017$51,000
-62.2%
3,534
-59.0%
0.01%
-61.5%
Q3 2017$135,000
+321.9%
8,614
+233.1%
0.01%
+333.3%
Q2 2017$32,000
-44.8%
2,586
-33.1%
0.00%
-50.0%
Q4 2016$58,000
+141.7%
3,864
+527.3%
0.01%
+50.0%
Q3 2015$24,0006160.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2016
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders